BACKGROUND AND OBJECTIVES:Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract. DA-6034 has been shown to be effective in an IBD model and has demonstrated a good toxicological profile in preclinical studies. This study evaluated the tolerability, safety and pharmacokinetics of DA-6034 in healthy volunteers. METHODS: A double-blind, randomized, placebo-controlled, ascending-dose study was conducted in 67 healthy volunteers. In the single-ascending-dose study, 10, 20, 50, 100 or 200 mg of DA-6034 was administered orally to 40 subjects; in the multiple-ascending-dose study, 40, 100 or 200 mg/day of DA-6034 was administered orally to 27 subjects for 7 days. Serial blood and urine samples were taken for pharmacokinetic analysis. Plasma drug concentrations were determined by high-performance liquid chromatography. Safety and tolerability were assessed throughout the study. RESULTS:DA-6034 had minimal absorption, and the pharmacokinetic parameters were highly variable among subjects. For both the single- and multiple-dose administrations, the coefficients of variation of the area under the plasma concentration-time curve to the last observation (AUClast) and the area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,τ) ranged from 16.0 to 125.0 %. At doses of up to 200 mg of DA-6034, the mean maximum plasma concentration (C max) was <3 ng/mL, and the urine recovery ratio was 0.3 % of the dose, indicating a lack of absorption. Twenty-two mild adverse events were reported in 14 subjects. There were no serious adverse events and no significant changes in the safety assessment. CONCLUSION:DA-6034 was well tolerated and minimally absorbed in healthy volunteers. The non-systemic, local exposure of the gastrointestinal tract to DA-6034 may be advantageous for IBD treatment.
RCT Entities:
BACKGROUND AND OBJECTIVES:Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract. DA-6034 has been shown to be effective in an IBD model and has demonstrated a good toxicological profile in preclinical studies. This study evaluated the tolerability, safety and pharmacokinetics of DA-6034 in healthy volunteers. METHODS: A double-blind, randomized, placebo-controlled, ascending-dose study was conducted in 67 healthy volunteers. In the single-ascending-dose study, 10, 20, 50, 100 or 200 mg of DA-6034 was administered orally to 40 subjects; in the multiple-ascending-dose study, 40, 100 or 200 mg/day of DA-6034 was administered orally to 27 subjects for 7 days. Serial blood and urine samples were taken for pharmacokinetic analysis. Plasma drug concentrations were determined by high-performance liquid chromatography. Safety and tolerability were assessed throughout the study. RESULTS:DA-6034 had minimal absorption, and the pharmacokinetic parameters were highly variable among subjects. For both the single- and multiple-dose administrations, the coefficients of variation of the area under the plasma concentration-time curve to the last observation (AUClast) and the area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,τ) ranged from 16.0 to 125.0 %. At doses of up to 200 mg of DA-6034, the mean maximum plasma concentration (C max) was <3 ng/mL, and the urine recovery ratio was 0.3 % of the dose, indicating a lack of absorption. Twenty-two mild adverse events were reported in 14 subjects. There were no serious adverse events and no significant changes in the safety assessment. CONCLUSION:DA-6034 was well tolerated and minimally absorbed in healthy volunteers. The non-systemic, local exposure of the gastrointestinal tract to DA-6034 may be advantageous for IBD treatment.
Authors: Hye J Chung; Young H Choi; Hye D Choi; Ji M Jang; Hyun J Shim; Moohi Yoo; Jong W Kwon; Myung G Lee Journal: Eur J Pharm Sci Date: 2006-01-04 Impact factor: 4.384
Authors: Craig Mowat; Andrew Cole; Al Windsor; Tariq Ahmad; Ian Arnott; Richard Driscoll; Sally Mitton; Tim Orchard; Matt Rutter; Lisa Younge; Charlie Lees; Gwo-Tzer Ho; Jack Satsangi; Stuart Bloom Journal: Gut Date: 2011-05 Impact factor: 23.059
Authors: Kelly Samara de Lira Mota; Guilherme Eduardo Nunes Dias; Meri Emili Ferreira Pinto; Anderson Luiz-Ferreira; Alba Regina Monteiro Souza-Brito; Clélia Akiko Hiruma-Lima; José Maria Barbosa-Filho; Leônia Maria Batista Journal: Molecules Date: 2009-03-03 Impact factor: 4.411
Authors: Jihyun Jung; Ki Young Huh; Xuanyou Jin; Ahnul Ha; Ki Ho Park; Jun Sang Park; Eunjung Kim; Jaehwi Lee; In-Jin Jang; Howard Lee Journal: Clin Transl Sci Date: 2021-09-15 Impact factor: 4.689